Guideline-based therapy
Phase 3Small molecule
Guideline-based therapy is one of 55 small molecule programs targeting Diabetes Mellitus, Type 2. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
119 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Tnkase
RochePhase 3
Ozempic
Novo NordiskPhase 3
Intravenous Thrombolysis
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Aggrastat
MMedicure
Phase 3
Rhtnk-Tpa
CCSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Phase 3
SGLT-2 Inhibitors
Novo NordiskPhase 3
Guideline-based therapy
GGeneral Hospital of Shenyang Military Region
Phase 3
PPA Intervention
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
SP-8203
SShin Poong Pharmaceutical Co. Ltd.
Phase 3
Y-6
BBeijing Tiantan Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Guideline-based therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details